GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » Degree of Operating Leverage

IOVA (Iovance Biotherapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Iovance Biotherapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Iovance Biotherapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.00. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Iovance Biotherapeutics's Degree of Operating Leverage or its related term are showing as below:

IOVA's Degree of Operating Leverage is not ranked *
in the Biotechnology industry.
Industry Median: -0.02
* Ranked among companies with meaningful Degree of Operating Leverage only.

Iovance Biotherapeutics Degree of Operating Leverage Historical Data

The historical data trend for Iovance Biotherapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Degree of Operating Leverage Chart

Iovance Biotherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Iovance Biotherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Iovance Biotherapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Iovance Biotherapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's Degree of Operating Leverage falls into.


;
;

Iovance Biotherapeutics Degree of Operating Leverage Calculation

Iovance Biotherapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -398.778 (Mar. 2025) / -467.425 (Mar. 2024) - 1 )/( 212.678 (Mar. 2025) / 1.904 (Mar. 2024) - 1 )
=-0.1469/110.7006
=-0.00***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Iovance Biotherapeutics  (NAS:IOVA) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Iovance Biotherapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Executives
Frederick G Vogt officer: General Counsel 2120 HEMLOCK RD., WEST NORRITON PA 19403
Ryan D Maynard director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wayne P. Rothbaum director C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Merrill A Mcpeak director PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wendy L Yarno director
Iain D. Dukes director 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky officer: Chief Operating Officer C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin officer: Chief Financial Officer C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg officer: VP, Finance C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf officer: Chief Medical Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris officer: Chief Financial Officer ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis director, officer: President and CEO C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085

Iovance Biotherapeutics Headlines

From GuruFocus